Skip to main content
6 search results for:

World Congress of Nephrology 2019 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 04-17-2019 | Nephropathy | Podcast | Article

    Nephrologist expert commentary: The CREDENCE trial

    Consultant nephrologist Andrew Frankel tells medwireNews about the rationale and key findings of the CREDENCE trial, and discusses the potential benefits of SGLT2 inhibitors beyond type 2 diabetes (9:45).

  2. 04-17-2019 | Nephropathy | Podcast | Article

    Primary care expert commentary: The CREDENCE trial

    General practitioner Kevin Fernando talks to medwireNews about the importance of the CREDENCE trial from a primary care perspective (4:43).

  3. 04-16-2019 | Nephropathy | Video | Article

    Diabetes expert commentary: The CREDENCE trial

    In this video interview, diabetes specialist John Wilding discusses how the CREDENCE trial findings may impact the treatment of people with type 2 diabetes and chronic kidney disease (3:31).

  4. 04-15-2019 | Nephropathy | Podcast | Article

    Researcher comment: The CREDENCE trial

    Lead investigator Vlado Perkovic talks about the main findings from the CREDENCE trial – demonstrating that canagliflozin is associated with a reduced risk for kidney failure and cardiovascular events in people with type 2 diabetes and chronic kidney disease – and discusses how these results will impact clinical practice (6:51).

  5. 04-15-2019 | Nephropathy | News | Article

    Canagliflozin may offer renal protection in people with type 2 diabetes and CKD

    As reported at the ISN World Congress of Nephrology 2019 in Melbourne, Victoria, Australia, and published simultaneously in The New England Journal of Medicine , the relative risk for the primary outcome of end-stage kidney disease, doubling of serum creatinine levels, or death from renal or cardiovascular causes was a significant 30% lower among participants treated with canagliflozin versus placebo.

  6. 04-17-2019 | Nephropathy | News | Article

    SONAR results support atrasentan for preserving renal function in type 2 diabetes

    Investigator Dick de Zeeuw (University of Groningen, the Netherlands) told delegates at the ISN World Congress of Nephrology 2019 in Melbourne, Victoria, Australia, that trial participants “were selected for a substantial albuminuria reduction and minimal clinical signs of sodium retention.”

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.